Purpose: To assess the effect of switching to brolucizumab from aflibercept on eyes with type 1 macular neovascularization (MNV) and polypoidal choroidal vasculopathy (PCV) at 18 months.
Methods: This study was a retrospective, observational case series that included 19 eyes of 19 patients with type 1MNV and 23 eyes of 22 patients with PCV. We compared the injection intervals, visual acuity, total lesion size, and the number of polypoidal lesions between baseline and 18 months. The correlations between the data including treatment interval, total lesion size, and the number of polyps were also assessed.
Results: Treatment intervals were significantly extended; from 7.4 ± 1.4 weeks to 11.6 ± 2.6 weeks for type 1 MNV, p < 0.001; from 6.9 ± 1.3 to 11.7 ± 3.1 weeks for PCV, p < 0.001. In type 1 MNV eyes, strong correlation was found between total lesion size and brolucizumab injection intervals (r = - 0.81; p = 0.0002) and moderate correlation was found between treatment frequency with aflibercept and that with brolucizumab (r = 0.76; p = 0.040). In PCV eyes, we found strong correlation between the number of polyps and brolucizumab treatment frequency (r = - 0.81; p = 0.0016) and moderate correlation between total lesion size and brolucizumab treatment interval (r = - 0.48; p = 0.034). Intraocular inflammation occurred in 2 of 19 eyes (10.3%) with type 1 MNV and 5 of 23 eyes (21.7%) with PCV.
Conclusion: The properties to extend brolucizumab injection intervals might be the smaller lesion size and lower aflibercept frequency for type 1 MNV and the smaller number of polyps and the smaller size of lesion for PCV.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00417-022-05793-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Brolucizumab for the Treatment of Diabetic Macular Edema: An Optical Coherence Tomography-Based Analysis.
Diagnostics (Basel)
December 2024
Eye Clinic, Department of Medical, Surgical Sciences and Health, University of Trieste, 34127 Trieste, Italy.
: The objectives of this study were to evaluate the structural and functional outcomes after the loading phase with brolucizumab in switched patients with diabetic macular edema (DME) and to identify potential predictive biomarkers of treatment response. : A total of 28 eyes with DME, switched to brolucizumab, were retrospectively reviewed. Main outcomes during the follow-up period, up to 6 weeks after the fifth injection, included changes in best-corrected visual acuity (BCVA), central subfield thickness (CST), macular volume, subfoveal choroidal thickness, intraretinal and subretinal fluid (IRF and SRF), cyst dimension including maximal horizontal cyst diameter (MHCD), maximal vertical cyst diameter (MVCD), width-to-height ratio (WHR), foveal avascular zone (FAZ) dimension, and vessel density (VD).
View Article and Find Full Text PDFInitial experience with brolucizumab for neovascular age-related macular degeneration (nAMD) in India - Multicentric, real-world study.
Indian J Ophthalmol
December 2024
Retina Department, Complete Eye Care Centre Manish Chamber, Mayur Vihar Phase-2, Delhi, India.
Purpose: To evaluate the anatomic and visual outcomes and safety profile of initial Indian eyes with neovascular age-related macular degeneration (nAMD) treated with intravitreal injection (IVI) of brolucizumab.
Methods: This retrospective multicentric, real-world study enrolled consecutive eyes with nAMD that were treated with IVI brolucizumab after it was launched in India in October 2020. Data collected for each eye included best-corrected visual acuity (BCVA), central subfield thickness (CSFT), subretinal fluid (SRF), and intraretinal fluid (IRF) status at 6, 12, and 24 months follow-up.
[Efficacy of brolucizumab in the treatment of retinal pathologies: a review of post-marketing studies].
Vestn Oftalmol
November 2024
S.M. Kirov Military Medical Academy, Saint Petersburg, Russia.
Brolucizumab, an angiogenesis inhibitor, is a single-chain fragment of a humanized antibody used to treat neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Although registration studies are the primary source of information on the new drug, post-marketing studies allow for further exploration and expansion of previous knowledge about its effectiveness, safety, and dosing regimens. This study summarizes the experience with brolucizumab from real-world clinical practice studies.
View Article and Find Full Text PDFFirst-year real-world experience of intravitreal brolucizumab injection for refractory neovascular age-related macular degeneration.
Jpn J Ophthalmol
November 2024
Department of Ophthalmology, Seoul National University College of Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea.
Article Synopsis
- The study aimed to assess the real-world effectiveness of brolucizumab injections for patients with neovascular age-related macular degeneration (nAMD) who did not respond to previous treatments.
- Results showed that while visual acuity (BCVA) remained stable, anatomical improvements were noted, such as decreased central foveal thickness (CFT) and reduced presence of subretinal fluid (SRF) and pigment epithelial detachment (PED) after switching to brolucizumab.
- The safety profile was acceptable, with a low incidence of intraocular inflammation-related adverse events reported among the patients.
Efficacy and safety of treat-and-extend intravitreal brolucizumab in naive and switched patients with macular neovascularization: one-year follow-up study.
BMC Ophthalmol
October 2024
Neuromuscular and Sense Organs Department, Eye Clinic, Careggi University Hospital, Florence, Italy.
Background: to analyze, at one year, the efficacy and safety of treat-and-extend (T&E) intravitreal (IV) Brolucizumab in patients affected by macular neovascularization (MNV). Both naïve and previously treated (i.e.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!